Positive News SentimentPositive NewsNASDAQ:AVIR Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis $4.72 -0.02 (-0.42%) As of 11:35 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Atea Pharmaceuticals Stock (NASDAQ:AVIR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atea Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.61▼$4.8250-Day Range$4.10▼$5.6552-Week Range$2.78▼$6.45Volume49,709 shsAverage Volume433,049 shsMarket Capitalization$377.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia. Through strategic collaborations with pharmaceutical partners and research institutes, the company enhances its R&D capabilities, optimizes clinical development pathways and positions its therapies for potential global commercialization. Atea’s leadership team brings extensive experience in antiviral drug discovery, clinical development and regulatory strategy. Under their guidance, the company has advanced multiple development candidates from preclinical stages into human trials. Atea continues to expand its scientific platform through in-licensing opportunities and collaborative research, with a goal of delivering safe and effective antiviral treatments to improve patient outcomes and respond to evolving public health challenges.AI Generated. May Contain Errors. Read More Atea Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreAVIR MarketRank™: Atea Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat, and ranked 777th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingAtea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAtea Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Atea Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($1.93) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atea Pharmaceuticals is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atea Pharmaceuticals is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtea Pharmaceuticals has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atea Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.14% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 16.04, which indicates bearish sentiment.Change versus previous monthShort interest in Atea Pharmaceuticals has recently decreased by 1.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtea Pharmaceuticals does not currently pay a dividend.Dividend GrowthAtea Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment1.89 News SentimentAtea Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atea Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atea Pharmaceuticals' insider trading history. Receive AVIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVIR Stock News HeadlinesAtea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus4 hours ago | globenewswire.comAtea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusJune 25, 2026 | globenewswire.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.July 14 at 1:00 AM | Porter & Company (Ad)Atea Shareholders Back Directors, Auditors and Executive PayJune 22, 2026 | tipranks.comAtea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV CatalystMay 29, 2026 | seekingalpha.comAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of ...May 28, 2026 | markets.businessinsider.comAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026May 27, 2026 | globenewswire.comHere's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn SituationMay 20, 2026 | finance.yahoo.comSee More Headlines AVIR Stock Analysis - Frequently Asked Questions How have AVIR shares performed this year? Atea Pharmaceuticals' stock was trading at $3.57 at the start of the year. Since then, AVIR shares have increased by 29.9% and is now trading at $4.6360. How were Atea Pharmaceuticals' earnings last quarter? Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) issued its earnings results on Tuesday, May, 12th. The company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.03. Read the conference call transcript. When did Atea Pharmaceuticals IPO? Atea Pharmaceuticals (AVIR) raised $288 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 12,500,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO. How do I buy shares of Atea Pharmaceuticals? Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atea Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atea Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), PayPal (PYPL) and Broadcom (AVGO). Company Calendar Last Earnings5/12/2026Today7/14/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 AVIR's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVIR CIK1593899 Webwww.ateapharma.com Phone857-284-8891FaxN/AEmployees70Year Founded2014Profitability EPS (Trailing Twelve Months)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$158.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.01% Return on Assets-51.49% Debt Debt-to-Equity RatioN/A Current Ratio7.89 Quick Ratio7.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.53 per share Price / Book1.34Miscellaneous Outstanding Shares80,030,000Free Float62,741,000Market Cap$377.74 million OptionableOptionable Beta0.31 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:AVIR) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredBNZI Lands a Zacks Upgrade!Banzai International (NASDAQ: BNZI) just received a Zacks Rank 2 (Buy) upgrade, driven by improving earnings e...Huge Alerts | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
